NovoCure develops and commercializes Tumor Treating Fields (TTFields), a non-invasive cancer therapy that uses alternating electric fields delivered via wearable devices to disrupt cancer cell division. Its best-known product, Optune, is used in glioblastoma and other solid tumor settings alongside conventional oncology care. The company differentiates itself with a device-based treatment modality rather than drugs alone, serving patients and clinicians in specialized oncology markets worldwide.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 155 | — | -34.3 | — |
| Q2 2025 | 158.8 | — | -40.1 | — |
| Q3 2025 | 167.2 | — | -37.3 | — |
| Q4 2025 | 174.3 | — | -24.5 | — |
| Q1 2026 | 174.1 | 12.3% | -71.1 | — |
| Q2 2026 | 183.6 | 15.6% | -15.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Bank First Corporation (BFC), newcleo plc (NWCL), Photronics, Inc. (PLAB), Kestra Medical Technologies, Ltd. (KMTS), Distribution Solutions Group, Inc. (DSGR), Zenas BioPharma, Inc. (ZBIO)